Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.78 USD
Change Today +0.02 / 2.63%
Volume 31.8K
CLTX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

celsus therapeutics-spon adr (CLTX) Snapshot

Open
$0.82
Previous Close
$0.76
Day High
$0.82
Day Low
$0.72
52 Week High
06/18/14 - $7.00
52 Week Low
04/13/15 - $0.67
Market Cap
4.3M
Average Volume 10 Days
49.0K
EPS TTM
$-1.70
Shares Outstanding
5.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELSUS THERAPEUTICS-SPON ADR (CLTX)

Related News

No related news articles were found.

celsus therapeutics-spon adr (CLTX) Related Businessweek News

No Related Businessweek News Found

celsus therapeutics-spon adr (CLTX) Details

Celsus Therapeutics Plc, a development stage biopharmaceutical company, engages in the discovery and development of non-steroidal, synthetic anti-inflammatory drugs. The company’s principal product candidate is MRX-6, a topical cream that is in Phase 2 clinical trial for the treatment of atopic dermatitis. Its product candidates in pre-clinical studies comprise OPT-1 for the treatment of conjunctivitis, post-operative inflammation, and/or dry eye; CFX-1 to treat cystic fibrosis; and OAX-1 for the treatment of osteoarthritis and other inflammatory diseases. The company was formerly known as Morria Biopharmaceuticals Plc and changed its name to Celsus Therapeutics Plc in June 2013. Celsus Therapeutics Plc was incorporated in 2004 and is headquartered in London, the United Kingdom.

5 Employees
Last Reported Date: 02/11/15
Founded in 2004

celsus therapeutics-spon adr (CLTX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $350.0K
Chief Financial Officer
Total Annual Compensation: $200.0K
Chief Medical Officer
Total Annual Compensation: $240.0K
Compensation as of Fiscal Year 2014.

celsus therapeutics-spon adr (CLTX) Key Developments

Celsus Therapeutics Plc Not In Compliance With NASDAQ Listing Rule

On April 9, 2015, Celsus Therapeutics Plc received a written notification from The NASDAQ Stock Market LLC ("NASDAQ") indicating that the Company was not in compliance with NASDAQ Listing Rule 5450(a)(2) because the minimum bid price of the Company's American Depositary Shares ("ADSs"), each representing ten (10) Ordinary Shares, par value £0.01, was below $1.00 per ADS for the previous 30 consecutive business days. Pursuant to the NASDAQ Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until October 6, 2015, to regain compliance with the minimum bid price requirement. During the compliance period, the Company's ADSs, will continue to be listed and traded on The NASDAQ Capital Market. To regain compliance, the closing bid price of the Company's ADSs must meet or exceed $1.00 per ADS for at least ten consecutive business days during this 180-day grace period. If the Company is not in compliance by October 6, 2015, the Company may be afforded a second 180-calendar day grace period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held ADSs and all other initial listing standards for The NASDAQ Capital Market, except for the minimum bid price. In addition, the Company would be required to notify NASDAQ of its intent to cure the minimum bid price deficiency by effecting a reverse stock split, if necessary. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by NASDAQ, NASDAQ will provide notice that the Company's ADSs will be subject to delisting. The Company would then be entitled to appeal NASDAQ's determination to a NASDAQ Hearings Panel and request a hearing. The Company intends to consider available options to resolve the noncompliance with the minimum bid price requirement. No determination regarding the Company's response has been made at this time. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other NASDAQ listing criteria.

Celsus Therapeutics Announces the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint

Celsus Therapeutics announced the results from C012013, a Phase II, double-blind, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of MRX-6 cream 2% in a pediatric population with mild to moderate atopic dermatitis. The trial enrolled 73 children with mild to moderate atopic dermatitis into a four-week double-blind period, followed by a four-week open label extension for those patients who wished to continue in the trial. Patients were randomized 1:1 in active and control arms of the trial.

Celsus Therapeutics Announces FDA Allowance of IND for Clinical Development of MRX-6 Cream in Atopic Dermatitis

Celsus Therapeutics announced that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug Application (IND) for the clinical development of MRX-6 Cream 2% in patients with atopic dermatitis. The FDA's allowance of the IND permits the Company to expand its clinical program in atopic dermatitis to the United States. The Company plans to initiate enrollment of a Phase II double blind, vehicle controlled, dose ranging trial of MRX-6 cream testing 0.1%, 1% and 2% vs vehicle in the first quarter of 2015. The upcoming Phase II trial will test three doses (0.1%, 1% and 2%) versus vehicle to evaluate the safety and efficacy of MRX-6 cream in a population with mild to moderate atopic dermatitis. The trial will enroll 168 patients into a four-week double-blind period. Results from this trial are expected in the first quarter of 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLTX:US $0.78 USD +0.02

CLTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLTX.
View Industry Companies
 

Industry Analysis

CLTX

Industry Average

Valuation CLTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELSUS THERAPEUTICS-SPON ADR, please visit www.celsustx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.